Antitumor |
Specific mIgG2A/hCD20 |
Mouse (humanized) |
EL4 expression hCD20 |
Tumor clearance; via ADCC; FcγRIV is required; engineered selective engagement of hFcγRIII is effective |
DiLillo and Ravetch (2015) |
Specific mIgG1/NYU‐seo‐1 |
Mouse |
Colon epithelial tumor |
Tumor inhibition; CD8 required; enhanced by chemotherapy; epitope spreading |
Noguchi et al (2012) |
Fusion of OVA to anti‐DEC205 antibody, DEC205 targeting etc. |
Mouse |
B16, HER2‐neu bearing tumor |
Enhanced tumor resistance, involvement of both CD4 and CD8 responses, enhanced by anti‐CD40 |
Wang et al (2012); Charalambous et al (2006); Bonifaz et al (2004) |
OVA epitope conjugated to anti‐DNGR‐1 (mouse or rat) |
Mouse |
B16 |
Tumor inhibition and prevention; metastasis inhibition; enhanced antigen uptake by CD8α+ DCs |
Sancho et al (2008) |
Specific mIgG2a mAb/HER2‐neu |
Mouse |
Her2 transgenic mouse |
IC‐mediated uptake of antigen by DCs; specific CD8 expansion; Fc required |
Kim et al (2008); Wolpoe et al (2003) |
Polyclonal rIgG/cell surface OVA |
Mouse |
Self‐antigen tolerance breaking |
Breaking CD8 tolerance of OVA transgene; requires FcγR γ‐chain and complement C3 |
Harbers et al (2007) |
IgG2A (TA99)/Gp75 |
Mouse |
B16 |
Tumor clearance; FcγRIV is required |
Nimmerjahn and Ravetch (2005) |
Specific mAb hIgG1 (B4‐B)/syndecan‐1 |
Human |
Myeloma |
CTL induction to unrelated testis antigen epitopes; reduced with anti‐FcγR antibodies |
Dhodapkar et al (2002) |
Specific rIgG/OVA |
Mouse |
B16 (OVA expressing) |
Mouse survival; FcR‐γ chain is required, absence of FcγIIB reduces tumor burden |
Kalergis and Ravetch (2002) |
Specific rIgG/OVA |
Mouse |
B16 (OVA expressing) |
Reduced tumor establishment; FcγR‐γ required; TAP and β2m required; MHC class II required |
Rafiq et al (2002) |
Vaccine |
bNAb/Ebola GP |
Macaque |
Ebola |
Protection against Ebola challenge, ADCC |
Corti et al (2016) |
bNAb/flu HA |
Mouse |
Influenza model |
Protection against influenza challenge, ADCC |
Wu et al (2015) |
IgG/TIV |
Mouse/human |
Influenza |
Early production of sialylated IgG set the threshold for subsequent high‐affinity and protective antibody production. |
Wang et al (2015b) |
Chicken polyclonal serum/NDV |
Chicken |
Newcastle disease |
Protection against viral challenge; some preparations reduced protection |
Yosipovich et al (2015); Rautenschlein et al (2007); Pokric et al (1993) |
bNAb/HIV gp120 |
Mouse (humanized) |
HIV model |
Longer period of aviremia after treatment; requires Fc portion for the effect |
Halper‐Stromberg et al (2014) |
Engineered bNAb/gp120 |
Mouse (humanized) |
HIV model |
Better protection against HIV entry; bNAb with Fc engineered to bind activating FcγR (humanized in mouse) are more effective |
Bournazos et al (2014) |
Specific mIgG2a/FT |
Mouse |
Francisella tularensis
|
Protection from subsequent challenges |
Pham et al (2014) |
Humanized mAb/RSV |
Cotton rat |
RSV |
G0 glycosylation is linked to better protection against RSV challenge |
Hiatt et al (2014) |
Pre‐made HBsAg IC |
Human |
HBV |
Induction of specific IgG1 and IgG3; reduced serum HBV DNA; reduced serum HBeAg; presence of anti‐HBeAg; increased HBeAg seroconversion |
Xu et al (2013); Yao et al (2007); Xu et al (2005) |
HBsAg fused to Fc of mIgG2a |
Mouse |
HBV model |
Higher specific CD8 activation; elevated CD4 response |
Hong et al (2011) |
Specific mIgG2a and mIgG1/FrCasE virus |
Mouse |
Model of HIV maternal transmission |
Reduced adolescent mortality from the virus; ADCC and CTL activations are involved |
Michaud et al (2010) |
Human IgG mAb/CD4 binding site of gp120 |
Mouse |
HIV model |
Higher anti‐gp120 titer; induction of neutralizing antibody |
Hioe et al (2009); Visciano et al (2008) |
Engineered specific hIgG1/P. falciparum
|
Mouse (humanized) |
Plasmodium berghei
|
Protection from lethality; FcR‐binding/FcγRI are critical |
McIntosh et al (2007) |
Chicken polyclonal serum/IBDV |
Chicken |
Chicken Bursal Disease |
Protection against viral challenge; immunization |
Ivan et al (2005); Giambrone et al (2001); Jeurissen et al (1998); Haddad et al (1997) |
IgG/HBsAg |
Mouse |
HBV model |
HBsAb seroconversion in HBV transgenic mice |
Zheng et al (2001) |
Non‐neutralizing IgG fraction/SIV gp120 |
Rhesus monkey |
SIV |
No protection, FcγRIIB signaling, anti‐inflammatory gene expression |
Polyanskaya et al (2001) |
Matrixed rat anti‐DHBV/DHBV |
Duck |
DHBV protection |
Reduced viral DNA and DHBsAg in serum |
Wen et al (1994) |
IgG/anti‐gp120 v3 loop |
Human |
HIV |
Positive anti‐HIV proliferation of CD4 T cells |
Berzofsky et al (1988) |
Human polyclonal IgG/HBV HBsAg |
Human |
In vitro antibody production |
Enhanced CD4 T‐cell activation; enhanced antibody production; requires Fc |
Celis et al (1987); Celis and Chang (1984); Celis et al (1984) |
Rabbit IgG/human or bovine albumin |
Mouse |
Vaccine efficacy |
Enhanced model antigen destruction in vivo
|
Terres and Wolins (1959a, 1961) |